Literature DB >> 14577003

Structural basis of the GM2 gangliosidosis B variant.

Fumiko Matsuzawa1, Sei-ichi Aikawa, Hitoshi Sakuraba, Hoang Thi Ngoc Lan, Akemi Tanaka, Kousaku Ohno, Yuko Sugimoto, Haruaki Ninomiya, Hirofumi Doi.   

Abstract

To study the structural basis of the GM2 gangliosidosis B variant, we constructed the three-dimensional structures of the human beta-hexosaminidase alpha-subunit and the heterodimer of the alpha- and beta-subunits, Hex A, by homology modeling. The alpha-subunit is composed of two domains, domains I and II. Nine mutant models due to specific missense mutations were constructed as well and compared with the wild type to determine structural defects. These nine mutations were divided into five groups according to structural defects. R178H is deduced to affect the active site directly, because R178 is important for binding to the substrate. C458Y and W420C are predicted to cause drastic structural changes in the barrel structure carrying the active site pocket. R504C/H is deduced to introduce a disruption of an essential binding with D494 in the beta-subunit for dimerization. R499C/H, located in an extra-helix, is deduced to disrupt hydrogen bonds with domain I and the barrel. R170W and L484P are deduced to affect the interface between domains I and II, causing destabilization. The structural defects reflect the biochemical abnormalities of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577003     DOI: 10.1007/s10038-003-0082-7

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  29 in total

1.  Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease.

Authors:  I Tews; A Perrakis; A Oppenheim; Z Dauter; K S Wilson; C E Vorgias
Journal:  Nat Struct Biol       Date:  1996-07

2.  Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

Authors:  Brian L Mark; Don J Mahuran; Maia M Cherney; Dalian Zhao; Spencer Knapp; Michael N G James
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

3.  GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene abnormalities in seven patients.

Authors:  A Tanaka; K Ohno; K Sandhoff; I Maire; E H Kolodny; A Brown; K Suzuki
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

4.  The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase.

Authors:  R Myerowitz; F C Costigan
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

5.  Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients.

Authors:  S Akli; J C Chomel; J M Lacorte; L Bachner; A Kahn; L Poenaru
Journal:  Hum Mol Genet       Date:  1993-01       Impact factor: 6.150

6.  A third mutation at the CpG dinucleotide of codon 504 and a silent mutation at codon 506 of the HEX A gene.

Authors:  B H Paw; L C Wood; E F Neufeld
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

7.  GM2-gangliosidosis B1 variant: a wide geographic and ethnic distribution of the specific beta-hexosaminidase alpha chain mutation originally identified in a Puerto Rican patient.

Authors:  A Tanaka; K Ohno; K Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1988-10-31       Impact factor: 3.575

8.  GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene mutations in 11 patients from a defined region in Portugal.

Authors:  M R dos Santos; A Tanaka; M C sá Miranda; M G Ribeiro; M Maia; K Suzuki
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

9.  Using known substructures in protein model building and crystallography.

Authors:  T A Jones; S Thirup
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

10.  Variant of GM2-gangliosidosis with hexosaminidase A having a severely changed substrate specificity.

Authors:  H J Kytzia; U Hinrichs; I Maire; K Suzuki; K Sandhoff
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  6 in total

1.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

Review 2.  The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.

Authors:  Gustavo H B Maegawa; Tracy Stockley; Michael Tropak; Brenda Banwell; Susan Blaser; Fernando Kok; Roberto Giugliani; Don Mahuran; Joe T R Clarke
Journal:  Pediatrics       Date:  2006-10-02       Impact factor: 7.124

Review 3.  Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.

Authors:  Elena Chiricozzi; Natalia Niemir; Massimo Aureli; Alessandro Magini; Nicoletta Loberto; Alessandro Prinetti; Rosaria Bassi; Alice Polchi; Carla Emiliani; Catherine Caillaud; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-12-20       Impact factor: 5.590

4.  Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.

Authors:  Kanako Sugawara; Seiji Saito; Kazuki Ohno; Torayuki Okuyama; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-03-14       Impact factor: 3.172

5.  Different attenuated phenotypes of GM2 gangliosidosis variant B in Japanese patients with HEXA mutations at codon 499, and five novel mutations responsible for infantile acute form.

Authors:  Akemi Tanaka; Lan Thi Ngcok Hoang; Yasuaki Nishi; Satoshi Maniwa; Makio Oka; Tsunekazu Yamano
Journal:  J Hum Genet       Date:  2003-10-18       Impact factor: 3.172

6.  Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India.

Authors:  Mehul Mistri; Parag M Tamhankar; Frenny Sheth; Daksha Sanghavi; Pratima Kondurkar; Swapnil Patil; Susan Idicula-Thomas; Sarita Gupta; Jayesh Sheth
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.